SCHEMBL15833537

SCHEMBL15833537

CC(=O)N1CCC(n2ccc3cnc(C)nc32)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
AURKA O14965 6/20 0.42
CDK1 P06493 2/20 0.42
AURKB Q96GD4 1/20 0.42
CDK4 P11802 4/20 0.38
INSR P06213 1/20 0.38
PDGFRB P09619 1/20 0.38
SRC P12931 1/20 0.38
PDGFRA P16234 1/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
CDK7 P50613 1/20 0.38
NTRK2 Q16620 1/20 0.38
BRD4 O60885 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15944040 0.84 PRMT5 (0.43) PRMT5WDR77AURKACDK1AURKB
SCHEMBL15833535 0.77 CHEK2 (0.39) PRMT5AURKACDK1CDK4INSR
SCHEMBL20351337 0.71 PRMT5 (0.37) PRMT5WDR77AURKACDK1AURKB
SCHEMBL17818386 0.71 MEN1 (0.48) PRMT5WDR77SRCKDR
SCHEMBL11977042 0.70 CDK4 (0.77) AURKACDK1AURKBCDK4INSR
SCHEMBL11977045 0.70 CDK4 (0.68) AURKACDK1CDK4INSRPDGFRB
SCHEMBL11977053 0.70 CDK4 (0.65) AURKACDK1CDK4INSRPDGFRB
SCHEMBL31735497 0.68 PRKCI (0.42) AURKABRD4ACACBACACA
SCHEMBL21671686 0.68 PRKCI (0.42) AURKABRD4ACACBACACA
SCHEMBL18711314 0.67 SPR (0.44) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777008-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-10-03 US disclosed
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-04-27 US disclosed
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-07-28 US disclosed
US-9388173-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2016-07-12 US disclosed
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-05-14 US disclosed
US-8906900-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2014-12-09 US disclosed
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-08-14 US disclosed
WO-2014100695-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 48/4885AURKA 1542/4885
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 54/4885AURKA 1174/4885
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 48/4885AURKA 1542/4885
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 48/4885AURKA 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.